Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Neurogene ( (NGNE) ) is now available.
Neurogene Inc. announced significant progress in its NGN-401 program for Rett syndrome, including the completion of dosing in a Phase 1/2 trial and initiation of the Embolden registrational trial. The company has received FDA agreement on trial elements and plans to report updated clinical data in late 2025. With a cash runway into early 2028, Neurogene is well-positioned to advance NGN-401, aiming to address the urgent need for new Rett syndrome treatments.
The most recent analyst rating on (NGNE) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Neurogene stock, see the NGNE Stock Forecast page.
Spark’s Take on NGNE Stock
According to Spark, TipRanks’ AI Analyst, NGNE is a Underperform.
Neurogene’s overall score is primarily influenced by its financial performance, which is challenged by zero revenues and significant net losses. While the stock shows some technical strength, the high beta and potential overbought conditions pose risks. The valuation reflects the speculative nature of investing in an early-stage biotech firm.
To see Spark’s full report on NGNE stock, click here.
More about Neurogene
Neurogene Inc. is a clinical-stage company focused on developing genetic medicines for rare neurological diseases. Their primary product is NGN-401, a gene therapy for Rett syndrome, with a market focus on providing new treatment options for patients and families affected by these conditions.
Average Trading Volume: 188,642
Technical Sentiment Signal: Sell
Current Market Cap: $302.6M
See more insights into NGNE stock on TipRanks’ Stock Analysis page.